Liraglutide · source year
7 selected, source-linked Liraglutide records carrying a 2025 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
7 selected records.
2 represented types.
7 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
Source: Federal Register via GovInfo ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 214568 with status AP dated 2025-08-27, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 215421 with status AP dated 2025-07-22, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218115 with status AP dated 2025-04-02, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗